Barinthus Biotherapeutics PLC. (BRNS) — 8-K Filings

8-K Filings (13)

• 8-K Filing — Dec 10, 2025
• Barinthus Biotherapeutics Enters Material Definitive Agreement — Sep 30, 2025 Risk: medium
  On September 29, 2025, Barinthus Biotherapeutics plc. entered into a material definitive agreement. The company, formerly known as Vaccitech plc, is a pharmaceu
• Barinthus Biotherapeutics plc Files 8-K — Jun 10, 2025 Risk: low
  On June 10, 2025, Barinthus Biotherapeutics plc. filed an 8-K report indicating a submission of matters to a vote of security holders. The company, formerly kno
• Barinthus Biotherapeutics Files 8-K — Jan 10, 2025 Risk: medium
  Barinthus Biotherapeutics plc. filed an 8-K on January 10, 2025, reporting on results of operations, costs associated with exit or disposal activities, and chan
• Barinthus Biotherapeutics CEO Change & Director Departure — Nov 25, 2024 Risk: medium
  Barinthus Biotherapeutics plc announced on November 25, 2024, the departure of Director Jonathan Jonathan and the appointment of Dr. Sarah Howell as Chief Execu
• Barinthus Biotherapeutics Files 8-K — Nov 15, 2024 Risk: low
  On November 15, 2024, Barinthus Biotherapeutics plc filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other event
• Barinthus Biotherapeutics Appoints Dr. Sarah Gilbert CSO — Sep 5, 2024 Risk: medium
  Barinthus Biotherapeutics plc announced on September 1, 2024, the appointment of Dr. Sarah Gilbert as Chief Scientific Officer and a new Director. Dr. Gilbert,
• Barinthus Biotherapeutics Appoints New CEO — Jun 12, 2024 Risk: medium
  On June 12, 2024, Barinthus Biotherapeutics plc announced the appointment of Dr. Sarah Howell as Chief Executive Officer, effective immediately. Dr. Howell, who
• Barinthus Biotherapeutics Files 8-K — Jun 6, 2024 Risk: low
  On June 6, 2024, Barinthus Biotherapeutics plc. filed an 8-K report. The filing primarily concerns other events and Regulation FD disclosures, with no specific
• Barinthus Biotherapeutics Holds AGM — May 15, 2024 Risk: low
  Barinthus Biotherapeutics plc announced on May 10, 2024, that it held its Annual General Meeting (AGM) where shareholders voted on several proposals. The compan
• Barinthus Biotherapeutics Files 8-K — May 13, 2024 Risk: low
  On May 13, 2024, Barinthus Biotherapeutics plc. filed an 8-K report detailing its financial results and operations. The company, formerly known as Vaccitech plc
• Barinthus Biotherapeutics Files 8-K — Apr 18, 2024 Risk: low
  On April 18, 2024, Barinthus Biotherapeutics plc filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no spec
• Barinthus Biotherapeutics Completes 1-for-13 Reverse Stock Split — Jan 5, 2024
  Barinthus Biotherapeutics plc filed an 8-K on January 5, 2024, to announce the completion of its previously disclosed reverse stock split. This means that for e

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX